drugset / Trial / NCT05013437
Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if Multiple Myeloma (MM) cells are sensitive to the chemotherapy used in transplant or not. The main chemotherapy agent utilized in stem cell transplant is melphalan. The study will utilize 1/10 of the dose used in transplant to study sensitivity of the tumor to melphalan. Melphalan is approved by the U.S. Food and Drug Administration (FDA) for transplant for MM patients.
Timeline
- Start
- 2023-09
- Primary completion
- 2023-12
- Completion
- 2024-03
Outcome
Outcome not reported
Stopped: “The original principal Investigator left the institution.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Melphalan | Small molecule | 16 mg/m2 | Intravenous |
| Background | Acetaminophen | Small molecule | 650 mg | Oral |
| Background | Diphenhydramine | Small molecule | 50 mg | Intravenous |
| Background | Prochlorperazine | Small molecule | 10 mg | Intravenous |